BioWorld

Sep. 12, 2003

XOMA Plans Public Offering Of 9M Shares Following Panel Nod

Two days after an FDA advisory panel recommended approval of its partnered psoriasis drug Raptiva, XOMA Ltd. disclosed plans for a public offering of 9 million common shares. (BioWorld Today) Read More

Enforcing Rule May Hamstring Companies Seeking SBIR Help

The Lancet Explores Whether Depression, Schizophrenia Both Arise From Similar Genetic Causes

House, Senate Committee Agrees On New Reimbursement Rates

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...